Dirithromycin (CAS 62013-04-1)

Dirithromycin, cataloged under CAS number 62013-04-1, is a macrolide antibiotic derivative known for its unique prodrug form, which upon administration is metabolized into its active component, erythromycylamine. It has been a focal point in non-clinical microbiological research due to its novel mode of action and transformation within biological systems. The primary mechanism of dirithromycin involves the inhibition of protein synthesis in bacterial cells. It achieves this by binding to the bacterial 50S ribosomal subunit, a critical component of the protein synthesis machinery. This binding impedes the translocation step of protein elongation, which is essential for the growth and replication of bacteria. This specific interaction disrupts the production of essential proteins, leading to bacterial growth inhibition and eventual bacterial cell death. In research settings, dirithromycin has been extensively used to study the dynamics of macrolide action, particularly its binding affinity and specificity towards the ribosomal subunit. Studies have also focused on the metabolic transformation of dirithromycin into its active form, providing insights into prodrug activation mechanisms that could influence the design of future antibiotics. Additionally, research involving dirithromycin has contributed to understanding how bacteria develop resistance to macrolides, which is critical for advancing knowledge on combating antibiotic resistance in various bacterial strains.